Correvio Pharma (CORV)

[RyGuy]

https://www.medscape.com/viewarticle/922079


PHILADELPHIA — A quick-acting, fast-clearing antiarrhythmic agent appeared both safe and effective for conversion of atrial fibrillation (AF) in the emergency department (ED) in a registry analysis that is part of the drug's case before regulators in the United States.
One or two short infusions of the drug, vernakalant (Brinavess, Correvio Pharma in Europe; Cipher Pharma in Canada), successfully cardioverted about 70% of episodes of recent-onset, symptomatic AF in more than 1000 patients tracked in the SPECTRUM registry.